The first family member, NDRG1, was originally identified as a target repressed by proto-oncogenes MYC and N-MYC (Shimono et al. 1999) and has since been studied under various aliases (e.g., RTP, Rit42, Cap43, PROXY1) in the contexts of cancer, hypoxia, and peripheral neuropathy (Kokame et al., 1996; Zhou et al., 1998; Piquemal et al.,1998;Echaniz-Laguna et al., 2007; Kachhap et al., 2007; Kitowska and Pawelczyk, 2010; Park et al., 2022). This evidence concerns the gene NDRG1 and peripheral neuropathy.